Craft

AstraZeneca

Stock Price

£121.7

2024-05-01

Market Capitalization

£184.2 B

2023-05-03

Revenue

$45.8 B

FY, 2023

AstraZeneca Summary

Company Summary

Overview
AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. It develops drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, gastroenterology, and other areas. The company offers its products to primary care and specialty care physicians.
Type
Public
Status
Active
Founded
1999
HQ
Cambridge, GB | view all locations
Website
https://www.astrazeneca.com/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Pascal Soriot

    Pascal Soriot, Executive Director and Chief Executive Officer

    • Johan Hyllner

      Johan Hyllner, Executive Director and Head of Cell Therapy, BioPharmaceuticals R&D

    • Hitesh Sanganee

      Hitesh Sanganee, Head of Emerging Innovations

    • Pam Cheng

      Pam Cheng, Executive Vice-President, Operations, Information Technology and Sustainability

    Operating MetricsView all

    Healthcare Workers Trained

    199K
    50.5%

    FY, 2021

    New Phase I Projects

    3

    Q2, 2022

    New Phase II Projects

    1
    75.0%

    Q2, 2022

    LocationsView all

    109 locations detected

    • Cambridge, England HQ

      United Kingdom

      1 Francis Crick Ave

    • Coral Gables, FL

      United States

      804 Douglas Rd #630

    • Gaithersburg, MD

      United States

      1 Medimmune Way

    • Gaithersburg, MD

      United States

      200 Orchard Ridge Dr

    • Gaithersburg, MD

      United States

      950 Wind River Ln

    • Rockville, MD

      United States

      1700 Rockville Pike #250

    and 103 others

    AstraZeneca Financials

    Summary Financials

    Revenue (FY, 2023)
    $45.8B
    Gross profit (FY, 2023)
    $39.8B
    Net income (FY, 2023)
    $6.0B
    Cash (FY, 2023)
    $5.8B
    EBIT (FY, 2023)
    $8.2B
    Enterprise value
    $207.0B

    Footer menu